

1 WHEREAS, despite explicitly prohibiting coverage for GLP-1s strictly indicated for
2 obesity treatment, Louisiana still expends two hundred million dollars annually on these
3 medications for diabetic members, while access for primary weight management remains
4 heavily restricted due to a sixteen thousand dollar annual cost per patient; and

5 WHEREAS, currently, Louisiana Medicaid covers GLP-1 medications only if the
6 patient has a qualifying body mass index and co-occurring conditions like type 2 diabetes
7 exist; and

8 WHEREAS, newer oral (pill) forms of GLP-1 receptor agonist drugs are available
9 for weight loss and type 2 diabetes management, eliminating the need for weekly injections;
10 and

11 WHEREAS, oral (pill) forms of GLP-1 medications approved through 2025 offer a
12 non-injectable alternative, yet they fail to offer cost savings as they are priced on par with
13 injectables, continuing to drive up commercial health insurance premiums; and

14 WHEREAS, to manage these extreme pharmacy benefit expenditures, public and
15 private insurers in 2026 are scaling back benefits, implementing strict utilization
16 management, such as prior authorizations and step-therapy rules, or terminating weight-loss
17 coverage entirely, leaving millions without access; and

18 WHEREAS, while the Centers for Medicare & Medicaid Services (CMS) has
19 introduced temporary bridge demonstrations offering select products at a fifty-dollar
20 monthly copay for eligible beneficiaries, broader structural coverage solutions are urgently
21 needed; and

22 WHEREAS, Louisiana must conduct a comprehensive evaluation of GLP-1
23 utilization and actuarial dynamics to develop sustainable solutions that expand necessary
24 healthcare access while protecting the fiscal health of the state and its citizens.

25 THEREFORE, BE IT RESOLVED that the Legislature of Louisiana does hereby
26 create and establish the PACE Task Force to study the history, accessibility, and insurance
27 costs of GLP-1 medications and to propose specific recommendations for legislation.

28 BE IT FURTHER RESOLVED that the legislature recommends that the PACE Task
29 Force, in its consideration, include but not be limited to the following topics:

1 (1) Whether GLP-1 medication pricing should differ for diabetes versus weight loss
2 indications.

3 (2) Whether plans covering GLP-1 medications attract higher-risk enrollees.

4 (3) Whether strict approval policies reduce insurer spending or shift costs elsewhere.

5 (4) Whether, and to what extent, employers restrict GLP-1 coverage to control
6 premium growth.

7 (5) Whether lower-income or uninsured populations disproportionately are excluded
8 due to costs.

9 (6) Causes why an insured or enrollee may discontinue GLP-1 medications after
10 only months of treatment.

11 (7) Actuarial projection models showing long-term net savings of GLP-1 coverage
12 over two, five, and ten years.

13 (8) Which form of GLP-1 medication is more cost-effective?

14 BE IT FURTHER RESOLVED that the task force shall consist of the following
15 members:

16 (1) The commissioner of insurance or his designee.

17 (2) The chief executive officer of the Louisiana Association of Health Plans or his
18 designee.

19 (3) The secretary of the Louisiana Department of Health or his designee.

20 (4) The chair of the Louisiana Board of Pharmacy or his designee.

21 (5) One representative that is a licensed healthcare provider who specializes in
22 endocrinology and obesity from a list of nominees submitted by Our Lady of the Lake,
23 Baton Rouge Clinic, or Woman's Metabolic Center appointed by the speaker of the House
24 of Representatives.

25 BE IT FURTHER RESOLVED that the task force shall be staffed by the Louisiana
26 Department of Insurance.

27 BE IT FURTHER RESOLVED that each designating authority shall submit the
28 names of designees to the task force to the Louisiana Department of Insurance no later than
29 August 1, 2026.

1 BE IT FURTHER RESOLVED that the task force shall convene its first meeting no
2 later than September 1, 2026.

3 BE IT FURTHER RESOLVED that the members of the task force shall serve
4 without compensation, except per diem or expenses reimbursement to which they may be
5 individually entitled as members of their constituent organizations.

6 BE IT FURTHER RESOLVED that the task force shall submit a written report
7 detailing its findings to the House and Senate committees on insurance no later than
8 February 12, 2027.

9 BE IT FURTHER RESOLVED that any written recommendations or proposals shall
10 also be submitted to the David R. Poynter Legislative Research Library as required by
11 R.S. 24:771 and 772.

12 BE IT FURTHER RESOLVED that the PACE Task Force shall terminate following
13 the conclusion of its business or by February 12, 2027, whichever occurs first.

14 BE IT FURTHER RESOLVED that a copy of this Resolution be transmitted to the
15 commissioner of the Louisiana Department of Insurance, the president of the Louisiana
16 Association of Health Plans, the secretary of the Louisiana Department of Health, and the
17 chair of the Louisiana Board of Pharmacy.

DIGEST

The digest printed below was prepared by House Legislative Services. It constitutes no part of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

HCR 120 Original

2026 Regular Session

Lyons

Creates the PACE Task Force to prioritize access, care and education on GLP-1 medications by studying their clinical history, accessibility, and effect on insurance costs for insureds and insurers in this state and to report their findings no later than Feb. 12, 2027.